REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$782.04
−1.10%Year over year
Reported trailing growth
- Revenue
- +9.3%
- EBITDA
- +6.1%
- EBIT
- +3.4%
- EPS
- +0.3%
- Free cash flow
- -8.4%
- Operating cash flow
- -6.3%
Forward estimates
Based on analyst estimates
- Revenue
- +22.5%
- EBITDA
- +45.3%
- EPS
- +55.0%
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- +3.4%
- EBIT
- -12.7%
- Net income
- +1.3%
- EPS
- +2.1%
- Free cash flow
- -2.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026